US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

22.51

+0.04500.20%

Volume:901

Turnover:20.28K

Market Cap:4.50M

PE:- -

High:22.51

Open:22.51

Low:22.51

Close:22.47

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:4.27

T/O Rate:0.45%

Dividend:0.08

Dividend Rate:0.35%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

Traders Reveal Reserve Bank of India Selling Dollars in FX Market to Prop Up Rupee

Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

AC Immune receives fast track designation, clearance for ACI-7104 IND

Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Press Release: Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Press Release: Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears

Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

Press Release: Entera Announces Second Quarter 2026 Financial Results and Business Updates

Press Release: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/IND/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":22.51,"timestamp":1789142570401,"preClose":22.465,"halted":0,"volume":901,"delay":0,"changeRate":0.002003115958157209,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Trading","change":0.045,"latestTime":"09-11 12:14:40 EDT","open":22.51,"high":22.51,"low":22.51,"amount":20280.985618,"amplitude":0,"askPrice":22.59,"askSize":100,"bidPrice":22.42,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789156800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":22.465,"sharesOutstanding":200001,"nav":22.614,"aum":4522844.8,"dividendRate":0.003492,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":22.425,"preClose":22.465,"latestTime":"16:10 EDT","volume":6,"amount":134.79,"timestamp":1789071007648,"change":-0.04,"changeRate":-0.001781,"amplitude":0},"volumeRatio":4.267809},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.267809,"shares":200001,"dividePrice":0.0786,"high":22.51,"amplitude":0,"preClose":22.465,"low":22.51,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":22.51,"committee":0.333333,"eps":0,"divideRate":0.003492,"volume":901,"delay":0,"ttmEps":0,"open":22.51,"prevYearClose":24.78,"prevWeekClose":23.125,"prevMonthClose":23.145,"prevQuarterClose":22.88,"fiveDayClose":23.195,"twentyDayClose":23.2218,"sixtyDayClose":22.81},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658908970","title":"Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908970","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908970?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:30","pubTimestamp":1786534200,"startTime":"0","endTime":"0","summary":"Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343546/0/en/xilio-therapeutics-reports-second-quarter-2026-financial-results-and-provides-pipeline-and-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","BK4539","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658089799","title":"TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658089799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658089799?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":"First patient dosed in Phase 3 ALLOHA-2 study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA study, validating internal commercial-ready manufacturing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343490/0/en/tscan-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EES","IND","BK4539","BK4139","LENZ","IDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658044979","title":"Press Release: Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658044979","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658044979?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532400,"startTime":"0","endTime":"0","summary":"-- Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAA","IND","BK4585","SPRE","CTEV","BK4563","BK4167","BK4215","AV","BK4139","R","BK4232","BK4022","BK4588","HUMA","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194634718","title":"Traders Reveal Reserve Bank of India Selling Dollars in FX Market to Prop Up Rupee","url":"https://stock-news.laohu8.com/highlight/detail?id=1194634718","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194634718?lang=en_us&edition=fundamental","pubTime":"2026-08-12 12:25","pubTimestamp":1786508739,"startTime":"0","endTime":"0","summary":"According to traders familiar with the matter, the Reserve Bank of India is selling US dollars in the onshore foreign exchange market to support the Indian rupee, as the currency faces pressure from...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FLIN","XCEM","SMIN","UUP","GLIN","GIND","IOPP","BK4523","INDA","INDE","INCO","BK4585","INDL","EPI","PIN","SCIN","NDIA","IND","ASGM","TAJX","UDN","BK4588","INDY","NFTY","FLIBF","INQQ","IMVP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658451129","title":"Press Release: Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658451129","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658451129?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:53","pubTimestamp":1786481580,"startTime":"0","endTime":"0","summary":"and the OLE  trial to assess the totality of. available efficacy and safety data and to support an informed. determination of next steps for the ARD-101 program. In June 2026, the. Company terminated the HERO and the OLE trial and does not currently. intend to resume these trials as previously designed.-- In May 2026, the Company announced that the U.S. Food and Drug. Administration  placed a full clinical hold on its investigational. new drug application  for ARD-101, related to the Company's. previously announced voluntary pause. The clinical hold applies to all. previously ongoing clinical studies under the IND, including the Phase 3. HERO trial evaluating ARD-101 for the treatment of hyperphagia in. patients with Prader-Willi Syndrome  and the Phase 3 OLE trial.Second Quarter 2026 Financial Highlights-- Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents. and short-term investments of $73.9 million, compared to $91.2 million as. of March 31, 2026. Based on curre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GDOC","IDNA","IND","BMED","AARD","HYLG","PWS","MEDX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997637","title":"AC Immune receives fast track designation, clearance for ACI-7104 IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997637","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997637?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:41","pubTimestamp":1786448502,"startTime":"0","endTime":"0","summary":"AC Immune (ACIU) announced that it has received fast track designation and clearance of its investigational new drug, or IND, application from the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ac-immune-receives-fast-track-designation-clearance-for-aci-7104-ind-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ac-immune-receives-fast-track-designation-clearance-for-aci-7104-ind-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4113","BK4139","IND","ACI","ACIU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994051","title":"Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994051?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446000,"startTime":"0","endTime":"0","summary":"at the 3rd International GBA1 Meeting 2026 in May 2026 in Phoenix, AZ.-- As of May 2026, all 16 participants enrolled in the Phase 1b,nine-month extension remained on study and had completed five. -- MDS-UPDRS scores remained stable and durable across the overall. study population after 150 days of treatment with rexaceract.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","TM","INN","LU1169589451.USD","BK4555","IND","BK4181","GANX","CSF","BK4588","GT","BK4139","BK4218","LU1169590202.USD","BK4119","PD","BK4023","BK4585","03160","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952508","title":"Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952508","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952508?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393200,"startTime":"0","endTime":"0","summary":"Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patien","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342259/0/en/palisade-bio-reports-second-quarter-2026-financial-results-and-highlights-continued-advancement-of-pali-2108-into-phase-2-development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","BK4006","LU2746668461.USD","LU2746668974.SGD","BK4127","CMC","LU0882574139.USD","IE00B1BXHZ80.USD","LU1363072403.SGD","BK4023","HYLG","PD","GDOC","LU1169589451.USD","LU0170899867.USD","LU1169590202.USD","PALI","LU2237443549.SGD","LU2237443622.USD","LU2237443895.HKD","IND","BK4116","IBD","BK4139","LU0971096721.USD","IE00BFXG1179.USD","LU0267386448.USD","LU2237443978.SGD","LU2237443382.USD","IE00BHPRN162.USD","LU2237443465.HKD","BK4007","IDNA","IE00BZ1G4Q59.USD","MEDX","CD","LU0149725797.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959548","title":"Press Release: Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959548","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959548?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"of the third quarter of 2026, including GLP toxicity. The Company remains. on track to submit an IND application in the fourth quarter of 2026 for. the global clinical program, and subject to regulatory clearance,-- Two Metagenomi scientific posters received Top Poster Awards at the 2026. International Society on Thrombosis and Haemostasias  Congress in. Paris, France, including one highlighting extensive non-human primate. preclinical data supporting MGX-001.MGX-001 - Large Gene Integration System for Protein Replacement via Gene Insertion-- The Company continues to evaluate disease indications which have the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","BK4539","MGX","IND","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952506","title":"Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952506","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952506?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342215/0/en/fractyl-health-reports-second-quarter-2026-financial-results-and-business-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","JDOC","GUTS","CTA","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995628","title":"Press Release: Olema Oncology Reports Second Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995628","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658995628?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:01","pubTimestamp":1786392060,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data. -- Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO. -- Announced a clinical trial collaboration and supply agreement with Bayer. to evaluate darolutamide in combination with OP-3136 in metastatic. -- Ended the second quarter with $461.1 million in cash, cash equivalents,palazestrant as a monotherapy in patients with second or third-line. estrogen receptor-positive (ER+), human epidermal growth factor receptor. -- Presented initial Phase 1 clinical data for OP-3136 as a monotherapy in. multiple solid tumor types and a trial-in-progress poster for the pivotal. Phase 3 OPERA-02 trial evaluating palazestrant in combination with. ribociclib in frontline ER+/HER2- MBC at the 2026 American Society of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBC","GDOC","OLMA","OP.USD.HKCC","BK4086","IND","HYLG","IDNA","BK4505","NVIB","BK4139","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658953571","title":"NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2658953571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658953571?lang=en_us&edition=fundamental","pubTime":"2026-08-10 22:34","pubTimestamp":1786372440,"startTime":"0","endTime":"0","summary":"Topline Results from Intranasal NEO100 in Recurrent IDH1-mutant High-grade Glioma could mark a Major Clinical Catalyst for NeOncDENVER, Aug.  10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) –NeOnc Technolog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341958/0/en/neonc-heads-into-a-high-stakes-week-as-highly-anticipated-neo100-phase-2a-data-readout-nears.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BBB","IND","BK4135","BK4007","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993909","title":"Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993909","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993909?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:01","pubTimestamp":1786366860,"startTime":"0","endTime":"0","summary":"Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governanceAppointment further streng","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4233","XBI","BK4581","IBB","BK4205","BK4585","BK4139","BBP","BK4588","RFL","BK4007","SYNB","IND","ERNA","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658493102","title":"NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2658493102","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658493102?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:30","pubTimestamp":1786365000,"startTime":"0","endTime":"0","summary":"Call to be held Wednesday, August 12, 2026 at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern TimeCALABASAS, Calif., Aug.  10, 2026  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“N","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341823/0/en/neonc-technologies-to-host-investor-conference-call-to-discuss-topline-phase-2a-results-for-intranasal-neo100-in-recurrent-idh1-mutant-high-grade-glioma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NVIB","MEDX","HST","BK4135","BK4218","BMED","HYLG","IDNA","GDOC","BK4181","BK4585","CNS","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936649","title":"Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936649","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936649?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models.MIAMI, Aug.  10, 2026  (GLOBE NEWSWIRE) ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341757/0/en/telomir-announces-peer-reviewed-publication-demonstrating-telomir-zn-suppresses-tumor-growth-in-tnbc-and-prostate-cancer-models.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IND","TELO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936592","title":"Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936592?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341783/0/en/cogent-biosciences-reports-recent-business-highlights-and-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCOI","LU1720051108.HKD","LU2357305700.SGD","LU0724618433.USD","LU1548497426.USD","LU0348723411.USD","LU1861214812.USD","IE00BZ199S13.USD","LU0124384867.USD","IE00BFMHRM44.USD","LU1861215975.USD","LU1861219969.SGD","BK4512","LU1720051017.SGD","LU1670628061.USD","BK4588","BK4141","BK4585","ON","LU1670627923.USD","BK4089","LU1983260115.SGD","BK4605","LU2360107325.USD","LU2298322129.HKD","LU1854104046.USD","LU1854103824.USD","IE00BD6J9T35.USD","BK4532","LU1861220033.SGD","IND","LU1978683503.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936984","title":"Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936984","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936984?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359600,"startTime":"0","endTime":"0","summary":"Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination Lucid-MS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341697/0/en/quantum-biopharma-receives-united-states-fda-clearance-to-proceed-with-lucid-ms-phase-2-trial-in-progressive-multiple-sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UBCP","QNTM","BK4504","BMED","LU1035773651.USD","LU2087625088.SGD","LU0912757837.SGD","BK4596","LU0971096721.USD","LCID","BK4532","IND","IE0005OL40V9.USD","LU2089284900.SGD","BK4099","BK4007","LU1481011671.HKD","BK4516","LU1244550221.USD","LU1668664300.SGD","PBE","IAI","BNDI","LCDL","LU0070302665.USD","LU1366192091.USD","IAK","LCIZ","BIIB","NBIX","PGR","LU2065170008.USD","LU0320765992.SGD","LU0772969993.USD","KBWB","IE0004445015.USD","LU0053666078.USD","LU1718418525.SGD","IE00B775H168.HKD","BK4139","LU0731783394.SGD","IE00BN29S564.USD","IE00BZ1G4Q59.USD","KBWP","LABU","LU1988902786.USD","CAGR","LU0889565916.HKD","LXRX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626861","title":"Press Release: Entera Announces Second Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626861","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626861?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:05","pubTimestamp":1786133100,"startTime":"0","endTime":"0","summary":"In June 2026, Entera announced that the FDA accepted Entera's plan to. conduct a single, randomized, double-blind, placebo-controlled Phase 3. trial in approximately 750 postmenopausal women with osteoporosis, with a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4232","PD","ENTX","KOL","R","BK4139","BK4022","KBWY","PK","IND","BK4218","LU1169590202.USD","BK4023","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610803","title":"Press Release: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610803","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610803?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":"Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12)Full year 2026 revenue guidance of $100.5 to $111.0 million affirmedNDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","IND","BK4023","CEO","BK4099","CHB","03160","BK4588","PD","BK4585","GDXJ","TM","SIL","CFO","BK4139","LU1169589451.USD","CDE","BK4555","LU1169590202.USD","XME","BK4017","LU1223082196.USD","LU1223083913.SGD","SGDM","LU1223082519.USD","GYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657226618","title":"CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2657226618","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657226618?lang=en_us&edition=fundamental","pubTime":"2026-08-07 15:38","pubTimestamp":1786088298,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics  said its investigational new drug application for CT1190B, an allogeneic CAR T-cell therapy targeting CD19/CD20, received clearance from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The clearance allows the company to begin a clinical trial of CT1190B in patients with relapsed or refractory large B-cell lymphoma who have failed at least two prior lines of standard therapy.z","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02171","BK1585","BK1574","BK4539","IND","BK4139","BK1587","LENZ","BK4007","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}